New Phase 2 Paid Hepatitis C Clinical Trial
September 17, 2012
The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.
For a detailed look at the description of the study, its objectives, inclusion criteria, as well as how to contact Avail Clinical Research and get started, click here: http://www.prweb.com/releases/trials/hepatitis-c/prweb9876722.htm
Are There Shades of Grey in Hepatitis C Treatment Success?
Gilead's Sofosbuvir Gets High Marks for HIV/HCV Co-Infection